DK0651746T3 - Lægemidler, der forbedrer synaptiske responser medieret af AMPA-receptorer - Google Patents
Lægemidler, der forbedrer synaptiske responser medieret af AMPA-receptorerInfo
- Publication number
- DK0651746T3 DK0651746T3 DK93918326T DK93918326T DK0651746T3 DK 0651746 T3 DK0651746 T3 DK 0651746T3 DK 93918326 T DK93918326 T DK 93918326T DK 93918326 T DK93918326 T DK 93918326T DK 0651746 T3 DK0651746 T3 DK 0651746T3
- Authority
- DK
- Denmark
- Prior art keywords
- drugs
- ampa receptors
- responses mediated
- synaptic responses
- enhance synaptic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91951292A | 1992-07-24 | 1992-07-24 | |
PCT/US1993/006916 WO1994002475A1 (en) | 1992-07-24 | 1993-07-23 | Drugs that enhance synaptic responses mediated by ampa receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0651746T3 true DK0651746T3 (da) | 2002-07-29 |
Family
ID=25442213
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01111268T DK1156043T3 (da) | 1992-07-24 | 1993-07-23 | Lægemidler, der forøger synaptiske reaktioner formidlet af ampa-receptorer |
DK93918326T DK0651746T3 (da) | 1992-07-24 | 1993-07-23 | Lægemidler, der forbedrer synaptiske responser medieret af AMPA-receptorer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01111268T DK1156043T3 (da) | 1992-07-24 | 1993-07-23 | Lægemidler, der forøger synaptiske reaktioner formidlet af ampa-receptorer |
Country Status (14)
Country | Link |
---|---|
US (2) | US5747492A (ko) |
EP (3) | EP1156043B1 (ko) |
JP (1) | JP4374082B2 (ko) |
KR (1) | KR100303523B1 (ko) |
AT (2) | ATE253909T1 (ko) |
AU (1) | AU688271B2 (ko) |
CA (2) | CA2138533C (ko) |
DE (2) | DE69333299T2 (ko) |
DK (2) | DK1156043T3 (ko) |
ES (2) | ES2210060T3 (ko) |
HK (1) | HK1042485B (ko) |
NZ (2) | NZ255097A (ko) |
PT (2) | PT1156043E (ko) |
WO (1) | WO1994002475A1 (ko) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1156043E (pt) | 1992-07-24 | 2004-03-31 | Univ California | Drogas que aumentam as respostas sinapticas mediadas por receptores de ampa |
US6274600B1 (en) * | 1995-06-05 | 2001-08-14 | The Regents Of The University Of California | Heteroatom substituted benzoyl derivatives that enhance synaptic responses mediated by AMPA receptors |
US5650409A (en) * | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
US5773434A (en) * | 1995-08-30 | 1998-06-30 | Gary A. Rogers | Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia |
JP2000507212A (ja) * | 1996-01-29 | 2000-06-13 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 性機能不全の治療方法 |
US5736543A (en) * | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
WO1997039750A1 (en) * | 1996-04-19 | 1997-10-30 | The Regents Of The University Of California | Treatment of mood/affective disorders by glutamatergic upmodulators |
US6030968A (en) * | 1996-09-17 | 2000-02-29 | The Regents Of The University Of California | Positive AMPA receptor modulation to enhance brain neurotrophic factor expression |
US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
US5985871A (en) * | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
US6124278A (en) * | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
PE20000942A1 (es) * | 1998-07-31 | 2000-09-28 | Lilly Co Eli | Derivados de amida, carbamato y urea |
US6011991A (en) * | 1998-12-07 | 2000-01-04 | Technology Patents, Llc | Communication system and method including brain wave analysis and/or use of brain activity |
TWI232863B (en) | 2001-06-11 | 2005-05-21 | Akzo Nobel Nv | Benzoxazepine derivatives |
JP4435562B2 (ja) | 2001-06-14 | 2010-03-17 | ナームローゼ・フエンノートチヤツプ・オルガノン | (ピリド/チエノ)−[f]−オキサゼピン−5−オン誘導体 |
US6562972B1 (en) * | 2001-07-19 | 2003-05-13 | Air Products And Chemicals, Inc. | Method for preparing heterocyclic-carboxylic acids |
EP1448537A4 (en) * | 2001-11-26 | 2005-05-04 | Cortex Pharma Inc | CARBONYLBENZOXAZINIC COMPOUNDS ENHANCING SYNAPTIC GLUTAMATERGIC RESPONSES |
NZ540468A (en) | 2003-01-13 | 2008-03-28 | Univ California | Method of treating cognitive decline due to sleep deprivation and stress using an AMPA receptor potentiator |
ATE556710T1 (de) * | 2004-01-26 | 2012-05-15 | Cortex Pharma Inc | Verbesserung der durch ampakine induzierten erleichterung von synaptischen reaktionen durch cholinesterase-inhibitoren |
US20060063707A1 (en) * | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
TW200800959A (en) | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
WO2007060144A2 (en) | 2005-11-22 | 2007-05-31 | Neurosearch A/S | Novel quinoxaline derivatives and their medical use |
WO2008027648A2 (en) * | 2006-06-26 | 2008-03-06 | Case Western Reserve University | Methods and compositions for treating pathologies associated with bdnf signaling |
CA2660431C (en) | 2006-08-31 | 2015-03-17 | The Governors Of The University Of Alberta | Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators |
WO2008028903A2 (en) | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
WO2008060375A2 (en) * | 2006-10-06 | 2008-05-22 | The Regents Of The University Of Californina | Upregulating bdnf levels to mitigate mental retardation |
US8173644B2 (en) * | 2007-01-03 | 2012-05-08 | Les Laboratoires Servier | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses |
KR20090098999A (ko) * | 2007-01-03 | 2009-09-18 | 코텍스 파마슈티칼스, 인크. | 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 3-치환된-[1,2,3]벤조트리아지논 화합물 |
TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
US8013003B2 (en) * | 2007-05-17 | 2011-09-06 | Cortex Pharmaceuticals, Inc. | Di-substituted amides for enhancing glutamatergic synaptic responses |
US8119632B2 (en) | 2007-08-10 | 2012-02-21 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
CA2695742C (en) * | 2007-08-10 | 2012-11-27 | Rudolf Mueller | Bicyclic amides for enhancing glutamatergic synaptic responses |
US8071914B2 (en) | 2007-12-26 | 2011-12-06 | Noboru Oshima | Heating apparatus |
US20110218190A1 (en) * | 2008-11-10 | 2011-09-08 | The Regents Of The University Of California | Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction |
EP2391621A4 (en) * | 2009-02-02 | 2012-07-25 | Cortex Pharma Inc | BICYCLIC AMIDE DERIVATIVES FOR ENHANCING SYNAPTIC GLUTAMATERGIC RESPONSES |
PT105083A (pt) | 2009-04-28 | 2011-07-25 | Univ De Coimbra | Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central |
US20130058915A1 (en) | 2010-03-02 | 2013-03-07 | Children's Medica Center Corporation | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
EP2801377B1 (en) | 2011-03-04 | 2019-08-07 | The Regents of The University of California | Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke |
WO2014117089A1 (en) | 2013-01-25 | 2014-07-31 | Case Western Reserve University | Compositions and methods for the treatment of pervasive development disorders |
BR112015031249A2 (pt) | 2013-06-13 | 2017-07-25 | Veroscience Llc | método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica |
CN107286114B (zh) | 2016-04-13 | 2020-08-18 | 中国人民解放军军事医学科学院毒物药物研究所 | Ampa受体增效剂的脑靶向前药及其医药用途 |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
WO2019133997A1 (en) | 2017-12-31 | 2019-07-04 | Neuroenhancement Lab, LLC | System and method for neuroenhancement to enhance emotional response |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
WO2020056418A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2456991A (en) * | 1946-01-16 | 1948-12-21 | Thompson Boyce Plant Res | 3, 4-methylenedioxyphenyl-propylene compound |
US2487179A (en) * | 1946-08-23 | 1949-11-08 | Thompson Boyce Plant Res | Organic compounds |
US2773062A (en) * | 1953-10-06 | 1956-12-04 | Thompson Boyce Plant Res | Organic compounds and insecticidal compositions |
FR1534547A (fr) * | 1966-08-23 | 1968-07-26 | May & Baker Ltd | Nouveaux sels d'ammonium quaternaires de semicarbazones et thiosemicarbazones et leur préparation |
US3869431A (en) * | 1973-03-12 | 1975-03-04 | Firestone Tire & Rubber Co | Polyamides and their production |
US4117228A (en) * | 1973-09-08 | 1978-09-26 | Eisai Co., Ltd. | 1,3-benzodioxol derivatives |
US3981864A (en) * | 1973-09-08 | 1976-09-21 | Eisai Co., Ltd. | 1,3-Benzodioxol derivatives |
CH583730A5 (ko) * | 1973-09-25 | 1977-01-14 | Wander Ag Dr A | |
US4025629A (en) * | 1974-01-07 | 1977-05-24 | The Upjohn Company | P-(trifluoromethylquinolylamino)benzamides, pharmaceutical dosage forms and method of treatment |
DE2757483C2 (de) * | 1977-12-22 | 1980-02-28 | Haarmann & Leimer Gmbh, 3450 Holzminden | Verfahren zur Herstellung von Il-peronylidencrotonsäureamiden |
DE2757506C2 (de) * | 1977-12-22 | 1980-02-14 | Haarmann & Reimer Gmbh, 3450 Holzminden | Verfahren zur Herstellung von Piperonylidencrotonsaureamiden |
CU21107A3 (es) * | 1978-02-10 | 1988-02-01 | Hoffmann La Roche | Pyrrolidines derivatives |
US4209517A (en) * | 1978-07-17 | 1980-06-24 | Unicler | α-Ethylenic alcohols and ketones, their preparation, and their use as medicaments |
FR2461710A1 (fr) * | 1979-07-16 | 1981-02-06 | Sarget Sa Labo | Nouvelles imines derivees de l'amino-5 benzodioxole-1,3 utiles comme medicaments |
DE3009542A1 (de) * | 1980-03-13 | 1981-09-24 | Henkel KGaA, 4000 Düsseldorf | Desodorierende kosmetische zusammensetzungen |
CH646149A5 (de) * | 1981-02-05 | 1984-11-15 | Hoffmann La Roche | Pyrrolidin-derivat. |
US4431662A (en) * | 1981-03-06 | 1984-02-14 | Hodgson Gordon L Jun | 1-(1,3-Benzodioxol-5-yl)-2-pyrrolidinone and its medicinal use |
ES8203877A1 (es) * | 1981-05-13 | 1982-04-01 | Ferrer Int | Procedimiento de obtencion de nuevos aminoderivados en posi-cion 1, del 1-(3',4'-metilendioxifenil)propan-2-ol |
US4438142A (en) * | 1982-03-05 | 1984-03-20 | Burroughs Wellcome Co. | Pharmaceutical combination |
US4543361A (en) * | 1983-08-29 | 1985-09-24 | Muchowski Joseph M | ±2-[Phenethyl]-5-[(3,4-methylenedioxy)-α-hydroxybenzyl]pyrrolidine antihypertensives and use thereas |
US4548949A (en) * | 1983-01-24 | 1985-10-22 | Syntex (U.S.A.) Inc. | +2-[(3,4-Methylenedioxy)phenethyl]-5-[(3-carboxamido-4-hydroxy)-α-hydroxybenzyl]pyrrolidines |
US4499100A (en) * | 1983-05-18 | 1985-02-12 | Syntex (U.S.A.) Inc. | Benzodioxanyl-hydroxyethyleneamino-piperidinyl acetanilides, ketones, esters and carbamates which effect immunity and calcium entry and β-blockade |
US4582909A (en) * | 1984-02-02 | 1986-04-15 | Warner-Lambert Company | Benzobicyclic lactam acids and derivatives as cognition activators |
JPS60163812A (ja) * | 1984-02-03 | 1985-08-26 | Zenyaku Kogyo Kk | 抗アレルギ−剤 |
IT1215587B (it) * | 1987-06-26 | 1990-02-14 | Roussel Maestretti Spa | Derivati della 1-benzoil2-oxo 5-alcossi pirrolidina, loro procedimento di preparazione e loro impiego come sostanza medicinale. |
US5284876A (en) * | 1988-02-26 | 1994-02-08 | Neuromedica, Inc. | Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents |
JPH02124884A (ja) * | 1988-07-08 | 1990-05-14 | Zhongguo Yixuekexueyuan Yaowo Yanjiusuo | N―置換アミド誘導体 |
JP2842888B2 (ja) * | 1989-05-19 | 1999-01-06 | 森永製菓株式会社 | リボヌクレアーゼインヒビターを有効成分とする癌細胞転移抑制剤 |
IT1231921B (it) * | 1989-06-12 | 1992-01-15 | Sigma Tau Ind Farmaceuti | 1-acil-2-pirrolidoni quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
US5132119A (en) * | 1989-07-31 | 1992-07-21 | Massachusetts Institute Of Technology | Treatment of hypertrophic wound healing disorders with calcium channel blockers |
SE464275B (sv) * | 1989-07-31 | 1991-04-08 | Aagerup Bengt | Ny anvaendning av beta-receptorblockerare foer beredning av ett preparat verksamt mot menieres sjukdom |
IE910939A1 (en) * | 1990-04-13 | 1991-10-23 | Neurosearch As | Use of benzodiazepine compounds |
FR2669029B1 (fr) * | 1990-11-14 | 1994-09-02 | Adir | Nouveaux derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
DK0498722T3 (da) * | 1991-02-07 | 1998-03-09 | Roussel Uclaf | Nye bicycliske nitrogenforbindelser substitueret med en benzylgruppe, fremgangsmåde til deres fremstilling, de opnåede nye intermediærer, deres anvendelse som lægemidler og de pharmaceutiske præparater som de indgår i |
US5070101A (en) * | 1991-02-14 | 1991-12-03 | Mount Sinai School Of Medicine Of The City University Of New York | Method and pharmaceutical composition for the treatment of schizophrenia |
US5104877A (en) * | 1991-02-25 | 1992-04-14 | Abbott Laboratories | Psoriasis treatment |
WO1992020327A1 (en) * | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
DE4119146C2 (de) * | 1991-06-11 | 2001-01-11 | Rehau Ag & Co | Polymer-Mischungen Verfahren zu ihrer Herstellung und ihre Verwendung |
US5298506A (en) * | 1992-05-08 | 1994-03-29 | Brigham And Women's Hospital | Use of guanylate cyclase inhibitors in the treatment of shock |
US6406868B1 (en) * | 1992-06-10 | 2002-06-18 | Nps Allelix Corporation | AMPA-binding human GluR1 receptors |
PT1156043E (pt) | 1992-07-24 | 2004-03-31 | Univ California | Drogas que aumentam as respostas sinapticas mediadas por receptores de ampa |
US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
US5488049A (en) * | 1993-12-10 | 1996-01-30 | Fidia - Georgetown Institute For The Neuro-Sciences | Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents |
US5665878A (en) * | 1994-08-31 | 1997-09-09 | Eli Lilly And Company | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives |
US5852008A (en) | 1995-01-24 | 1998-12-22 | The Regents Of The University Of California | Heteroatom substituted benzoyl derivatives that enhance synaptic response mediated by receptors |
US5773434A (en) | 1995-08-30 | 1998-06-30 | Gary A. Rogers | Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia |
AU745641B2 (en) | 1997-10-27 | 2002-03-28 | Cortex Pharmaceuticals, Inc. | Treatment of schizophrenia with ampakines and neuroleptics |
-
1993
- 1993-07-23 PT PT01111268T patent/PT1156043E/pt unknown
- 1993-07-23 DK DK01111268T patent/DK1156043T3/da active
- 1993-07-23 EP EP01111268A patent/EP1156043B1/en not_active Revoked
- 1993-07-23 JP JP50469994A patent/JP4374082B2/ja not_active Expired - Fee Related
- 1993-07-23 EP EP03016192A patent/EP1367056A1/en not_active Withdrawn
- 1993-07-23 PT PT93918326T patent/PT651746E/pt unknown
- 1993-07-23 US US08/374,584 patent/US5747492A/en not_active Expired - Lifetime
- 1993-07-23 DE DE69333299T patent/DE69333299T2/de not_active Expired - Lifetime
- 1993-07-23 AU AU47815/93A patent/AU688271B2/en not_active Ceased
- 1993-07-23 AT AT01111268T patent/ATE253909T1/de not_active IP Right Cessation
- 1993-07-23 KR KR1019950700260A patent/KR100303523B1/ko not_active IP Right Cessation
- 1993-07-23 DK DK93918326T patent/DK0651746T3/da active
- 1993-07-23 EP EP93918326A patent/EP0651746B1/en not_active Expired - Lifetime
- 1993-07-23 CA CA002138533A patent/CA2138533C/en not_active Expired - Lifetime
- 1993-07-23 WO PCT/US1993/006916 patent/WO1994002475A1/en active IP Right Grant
- 1993-07-23 ES ES01111268T patent/ES2210060T3/es not_active Expired - Lifetime
- 1993-07-23 CA CA002450801A patent/CA2450801C/en not_active Expired - Lifetime
- 1993-07-23 AT AT93918326T patent/ATE215079T1/de active
- 1993-07-23 NZ NZ255097A patent/NZ255097A/en not_active IP Right Cessation
- 1993-07-23 ES ES93918326T patent/ES2174851T3/es not_active Expired - Lifetime
- 1993-07-23 DE DE69331761T patent/DE69331761T2/de not_active Expired - Lifetime
-
1994
- 1994-02-03 NZ NZ510375A patent/NZ510375A/xx not_active IP Right Cessation
-
1995
- 1995-06-05 US US08/461,235 patent/US5891876A/en not_active Expired - Lifetime
-
2002
- 2002-05-17 HK HK02103739.8A patent/HK1042485B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1042485B (zh) | 2004-03-05 |
AU4781593A (en) | 1994-02-14 |
EP1156043A3 (en) | 2001-12-05 |
DE69331761D1 (de) | 2002-05-02 |
WO1994002475A1 (en) | 1994-02-03 |
CA2450801A1 (en) | 1994-02-03 |
JP4374082B2 (ja) | 2009-12-02 |
US5891876A (en) | 1999-04-06 |
PT1156043E (pt) | 2004-03-31 |
EP0651746B1 (en) | 2002-03-27 |
EP1156043B1 (en) | 2003-11-12 |
ES2174851T3 (es) | 2002-11-16 |
ES2210060T3 (es) | 2004-07-01 |
US5747492A (en) | 1998-05-05 |
KR950702550A (ko) | 1995-07-29 |
EP1156043A2 (en) | 2001-11-21 |
ATE215079T1 (de) | 2002-04-15 |
KR100303523B1 (ko) | 2001-11-22 |
CA2138533A1 (en) | 1994-02-03 |
ATE253909T1 (de) | 2003-11-15 |
PT651746E (pt) | 2002-09-30 |
NZ255097A (en) | 2001-04-27 |
EP0651746A1 (en) | 1995-05-10 |
DK1156043T3 (da) | 2004-03-01 |
JPH07509468A (ja) | 1995-10-19 |
DE69331761T2 (de) | 2002-09-12 |
NZ510375A (en) | 2003-04-29 |
AU688271B2 (en) | 1998-03-12 |
DE69333299D1 (de) | 2003-12-18 |
DE69333299T2 (de) | 2004-09-09 |
HK1042485A1 (en) | 2002-08-16 |
CA2450801C (en) | 2009-11-17 |
EP1367056A1 (en) | 2003-12-03 |
CA2138533C (en) | 2009-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0651746T3 (da) | Lægemidler, der forbedrer synaptiske responser medieret af AMPA-receptorer | |
MX9203755A (es) | Dispositivo de suministro iontoforetico de drogas o agentes terapeuticos, dotado de un adhesivo de electrotransporte. | |
SE9102072D0 (sv) | Oral, fast, farmaceutisk doseringsform med styrd frisaettning | |
ES2091877T3 (es) | Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia. | |
ATE71837T1 (de) | Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe. | |
BR9206072A (pt) | Combinações de cálcio, traços de minerais, vitamina D e terapias com medicamentos. | |
DK485588D0 (da) | Doseringsform omfattende hurtig (laege)middellevering efterfulgt af langsom (laege)middellevering | |
ATE123489T1 (de) | 2-cyano-1,3-dionherbizide. | |
FI935398A (fi) | Skumreglerande medel i granulaer form | |
FR2684543B1 (fr) | Ligament artificiel, notamment pour la cheville. | |
FI894121A (fi) | 2-atsa-4-(alkoksikarbonyyli)spiro/4,5/dekan-3-oni | |
NO863625D0 (no) | Medikamentdoseringsanordning. | |
FI954614A (fi) | Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina | |
DE69322177D1 (de) | 8-(1-Aminocycloalkyl)-1,3-Dialkylxanthinderivate als Antagonisten von Adenosinrezeptoren | |
DE58907810D1 (de) | 3-Basisch substituierte 2-Methylfluorane. | |
DK0454429T3 (da) | Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme | |
AR002996A1 (es) | Isoxazolinas mejoradas antagonistas del receptore de fibrinogeno. | |
DE68905082D1 (de) | Virushemmende pharmazeutische zusammensetzung. | |
SE9304236D0 (sv) | New use | |
ES2039610T3 (es) | Medicamentos para el tratamiento de la artritis reumatoide. | |
FI892288A0 (fi) | Farmaceutiska loesningar av triamteren. | |
DE68900523D1 (de) | Ausgabevorrichtung mit hin- und hergehender bewegung. | |
DE58907941D1 (de) | Substituierte 2-(Halogenmethylthio)-pyrimidin-Derivate. | |
ES1014509Y (es) | Dispositivo para la administracion de farmacos por via uretral. | |
ES1007802Y (es) | Mecanismo para muneca andadora. |